ARL4C and skin basal cell carcinoma: Based on our preliminary findings, there was a notable variance in ARL4C expression between malignant cells and macrophages within certain tumor types, such as the BCC immunotherapy cohort, when comparing the treated cohorts to their untreated counterparts (Figure 6A).